Compare AYTU & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AYTU | ATCH |
|---|---|---|
| Founded | N/A | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 29.6M |
| IPO Year | 2015 | 2024 |
| Metric | AYTU | ATCH |
|---|---|---|
| Price | $1.85 | $0.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $9.67 | $1.00 |
| AVG Volume (30 Days) | 21.6K | ★ 900.5K |
| Earning Date | 11-20-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | ★ $27,632,080.00 | $20,052,635.00 |
| Revenue This Year | $17.96 | $32.20 |
| Revenue Next Year | $27.98 | N/A |
| P/E Ratio | ★ N/A | $7.02 |
| Revenue Growth | ★ 277.47 | 84.70 |
| 52 Week Low | $1.83 | $0.14 |
| 52 Week High | $3.07 | $0.38 |
| Indicator | AYTU | ATCH |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 31.78 |
| Support Level | N/A | N/A |
| Resistance Level | $2.34 | $0.21 |
| Average True Range (ATR) | 0.09 | 0.01 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 27.03 | 20.86 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.